Real‐world clinical experience with NGS‐based chimerism analyses in haematopoietic stem cell transplant patients
Open Access
- 4 June 2025
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 207 (2) , 475-483
Abstract
Summary: Next‐generation sequencing (NGS) has improved the sensitivity of chimerism assays beyond the limitations of conventional short tandem repeat (STR) methods, enabling the detection of minimal recipient haematopoiesis after haematopoietic stem cell transplantation (HSCT). We evaluated the clinical utility of CASAL, an NGS‐based chimerism assay, in routine practice. We retrospectively analysed 310 patients who underwent STR or CASAL chimerism testing between April 2021 and September 2023. CASAL provided significantly more informative markers than STR (median 18 vs. 6; p < 0.001). Among 260 CASAL samples with paired molecular minimal residual disease (MRD) data, concordance at the 10−4 threshold was ~84%. Low‐level mixed chimerism (2%–5%) detected beyond 1 month post‐HSCT was associated with impending relapse. In survival analyses, patients with both MC and MRD positivity (MC/MRD+) had the highest relapse risk across both platforms. Multivariable Cox regression confirmed MC/MRD+ as an independent predictor of relapse (hazard ratio 5.87, 95% CI: 1.17–29.57). CASAL enables sensitive chimerism monitoring and shows a strong correlation with molecular MRD and clinical outcomes. These findings support its clinical utility for individualized post‐HSCT surveillance, especially in patients lacking leukaemia‐specific molecular targets.Keywords
Funding Information
- National Research Foundation of Korea (NRF‐2022R1I1A1A01068590, RS‐2024‐00360261)
This publication has 24 references indexed in Scilit:
- Engraftment and Measurable Residual Disease Monitoring after Hematopoietic Stem Cell TransplantationThe Journal of Molecular Diagnostics, 2024
- Chimerism Assay Using Single Nucleotide Polymorphisms Adjacent and in Linkage-Disequilibrium Enables Sensitive Disease Relapse Monitoring after Hematopoietic Stem-Cell TransplantationClinical Chemistry, 2021
- Personalized Chimerism Test that Uses Selection of Short Tandem Repeat or Quantitative PCR Depending on Patient's Chimerism StatusThe Journal of Molecular Diagnostics, 2019
- Evaluation of Chimerism Dynamics after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Nonmalignant DiseasesTransplantation and Cellular Therapy, 2018
- Molecular Minimal Residual Disease in Acute Myeloid LeukemiaNew England Journal of Medicine, 2018
- Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic LeukemiaJAMA Oncology, 2017
- Assessment of Minimal Residual Disease in Standard-Risk AMLNew England Journal of Medicine, 2016
- Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2015
- Chimerism analysis in peripheral blood using indel quantitative real-time PCR is a useful tool to predict post-transplant relapse in acute leukemiaBone Marrow Transplantation, 2014
- Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCTBone Marrow Transplantation, 2014